A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection
Clinical trial NCT04981665 · UNKNOWN
Trial details
- NCT number
- NCT04981665
- Sponsor
- Zhejiang University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-08
- Primary completion
- 2024-12-01
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.